{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:39:29Z","timestamp":1785843569171,"version":"3.56.0"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            To determine suitability for national serosurveys, we compared two commercial enzyme-linked immunosorbent assays (ELISAs) for mumps antibody, Enzygnost Anti-Parotitis-Virus\/IgG (which uses a whole-virus antigen) and Microimmune Mumps IgG Screen ELISA (which uses a recombinant nucleoprotein antigen), by testing 1,915 opportunistically collected sera submitted to diagnostic laboratories across Australia in 1997 to 1998. The proportion of positive results increased with age in both ELISAs but was significantly higher with the Microimmune than with the Enzygnost ELISA overall (88% versus 63%;\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01) and in all age groups. However, the proportion of equivocal results was significantly higher with the Enzygnost than with the Microimmune ELISA (9% versus 4%;\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). Of the 572 sera with discrepant or equivocal results, 508 had sufficient sample remaining to perform the neutralization test (NT). A proportion with concordant results in both ELISAs were also tested by the NT. For sera with discrepant results, there was significantly better agreement between the NT and Microimmune than between the NT and Enzygnost (310\/444 [70%] versus 135\/348 [39%];\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). Of 64 sera with equivocal Microimmune results, 45 (70%) were positive in the NT compared with 140 of 160 (88%) equivocal Enzygnost results (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.01). Compared with the NT, the Microimmune ELISA is more sensitive (96% versus 80%) but apparently less specific (36% versus 85%) than the Enzygnost ELISA. However, this is likely to be due to the generally lower sensitivity of the NT, since the Microimmune results reflect expected seroprevalence, based on vaccine uptake in the age groups studied. We conclude that the Microimmune ELISA is a more appropriate assay than the Enzygnost ELISA for estimation of mumps seroprevalence.\n          <\/jats:p>","DOI":"10.1128\/cvi.00199-05","type":"journal-article","created":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T19:12:52Z","timestamp":1152299572000},"page":"764-767","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of Two Enzyme Immunoassays for Detection of Immunoglobulin G Antibodies to Mumps Virus"],"prefix":"10.1128","volume":"13","author":[{"given":"J. L.","family":"Backhouse","sequence":"first","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead"},{"name":"National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F.","family":"Gidding","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead"},{"name":"National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. B.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead"},{"name":"National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead"},{"name":"National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"135","year":"2003","unstructured":"Centers for Disease Control and Prevention. 2003. Mumps, p. 135-143. In Epidemiology and prevention of vaccine-preventable diseases, the pink book, 8th ed. National Immunization Program, U.S. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Ga.","journal-title":"National Immunization Program"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/1045-1056(90)90009-O","volume":"18","year":"1990","unstructured":"Christenson, B., and M. Bottiger. 1990. Methods for screening the naturally acquired and vaccine induced immunity to mumps virus. Biologicals18:213-219.","journal-title":"Biologicals"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jviromet.2005.08.001","volume":"131","year":"2006","unstructured":"Cohen, B. J., R. P. Parry, D. Doblas, D. Samuel, L. Warrener, N. Andrews, and D. Brown. 2006. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J. Virol. Methods131:209-212.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/infdis\/119.6.654","volume":"119","year":"1969","unstructured":"Ennis, F. A. 1969. Immunity to mumps in an institutional epidemic: correlation of insusceptibility to mumps with serum plaque neutralizing and haemagglutination-inhibiting antibodies. J. Infect. Dis.119:654-657.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_6_2","first-page":"409","volume":"31","year":"1987","unstructured":"Fedova, D., M. Bruckova, V. Plesnick, D. Slonim, J. Sejda, E. Svandova, and I. Kibinova. 1987. Detection of post vaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive haemagglutination test. J. Hyg. Epidemiol. Microbiol. Immunol.31:409-422.","journal-title":"J. Hyg. Epidemiol. Microbiol. Immunol."},{"key":"e_1_3_2_7_2","first-page":"503","volume":"32","year":"1988","unstructured":"Frankova, V., J. Holubova, L. Grubhoffer, and V. Kasova. 1988. Contribution to laboratory diagnosis of mumps and parainfluenza. Acta Virol.32:503-514.","journal-title":"Acta Virol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5694\/j.1326-5377.2001.tb143144.x","volume":"174","year":"2001","unstructured":"Gidding, H. F., M. A. Burgess, and A. E. Kempe. 2001. A short history of vaccination in Australia. Med. J. Aust.174:37-40.","journal-title":"Med. J. Aust."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1017\/S0950268801005830","volume":"127","year":"2001","unstructured":"Gilbert, G. L., R. G. Escott, H. F. Gidding, F. M. Turnbull, T. C. Heath, P. B. McIntyre, and M. A. Burgess. 2001. Impact of the Australian Measles Control Campaign on immunity to measles and rubella. Epidemiol. Infect.127:297-303.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.8.2139-2144.1992"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJM196702022760502","volume":"276","year":"1967","unstructured":"Hilleman, M. R., E. B. Weibel, J. Bunyak, J. Stokes, Jr., and J. E. Whitman. 1967. Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N. Engl. J. Med.276:252-258.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_12_2","first-page":"S1","volume":"24","year":"2000","unstructured":"McIntyre, P., J. Amin, H. Gidding, B. Hull, S. Torvaldsen, A. Tucker, F. Turnbull, and M. Burgess. 2000. Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998. Commun. Dis. Intell.24(Suppl.):S1-S83.","journal-title":"Commun. Dis. Intell."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S0950268803008768","volume":"131","year":"2003","unstructured":"Nardone, A., R. G. Pebody, S. van den Hof, D. Levy-Bruhl, A. M. Plesner, M. C. Rota, A. Tischer, N. Andrews, G. Berbers, P. Crovari, W. J. Edmunds, G. Garbutti, P. Saliou, and E. Miller. 2003. Sero-epidemiology of mumps in Western Europe. Epidemiol. Infect.131:691-701.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0166-0934(86)90077-7","volume":"13","year":"1986","unstructured":"Nigro, G., F. Nanni, and M. Midulla. 1986. Determination of vaccine-induced and naturally acquired class specific mumps antibodies by two indirect enzyme-linked immunosorbent assays. J. Virol. Methods13:91-106.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_15_2","first-page":"219","volume":"79","year":"1992","unstructured":"Pipkin, P. A., M. A. Afzal, A. B. Heath, and P. D. Minor. 1992. Assay of humoral immunity to mumps. J. Virol. Methods79:219-225.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.19.1.21-25.1984"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/infdis\/149.5.810","volume":"149","year":"1984","unstructured":"Shehab, Z. M., P. A. Brunell, and E. Cobb. 1984. Epidemiological standardization of a test for susceptibility to mumps. J. Infect. Dis.149:810-812.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/S0950268803008641","volume":"131","year":"2003","unstructured":"van den Hof, S., M. T. A. Beaumont, G. A. M. Berbers, and H. E. de Melker. 2003. Antibodies against mumps in The Netherlands as assessed by indirect ELISA and virus neutralization assay. Epidemiol. Infect.131:703-709.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S095026889900343X","volume":"124","year":"2000","unstructured":"Wehner, H., R. Morris, M. Logan, D. Hunt, L. L. Jin, J. Stuart, and K. Cartwright. 2000. A secondary school outbreak of mumps after the childhood immunisation programme in England and Wales. Epidemiol. Infect.124:131-136.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_20_2","first-page":"346","volume":"76","year":"2001","unstructured":"World Health Organization. 2001. Mumps virus vaccines. Wkly. Epidemiol. Rec.76:346-355.","journal-title":"Wkly. Epidemiol. Rec."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00199-05","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00199-05","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:15Z","timestamp":1627591035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00199-05"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1128\/CVI.00199-05"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00199-05","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"2005-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}